XML 36 R25.htm IDEA: XBRL DOCUMENT
v3.23.2

REVENUES (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2023
Revenue from Contract with Customer [Abstract] |
Summary of Disaggregation of Revenues | The following table summarizes our Total revenues:
|  | Three Months Ended June 30, 2023 |  | Three Months Ended June 30, 2022
(in millions) |  | U.S. |  | Europe |  | Other International |  | Total |  | U.S. |  | Europe |  | Other International |  | Total
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HIV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biktarvy |  | $ | 2,439 |  |  | $ | 302 |  |  | $ | 237 |  |  | $ | 2,979 |  |  | $ | 2,095 |  |  | $ | 268 |  |  | $ | 193 |  |  | $ | 2,556 |
Complera/Eviplera |  | 13 |  |  | 16 |  |  | 3 |  |  | 32 |  |  | 20 |  |  | 31 |  |  | 3 |  |  | 54 |
Descovy |  | 460 |  |  | 25 |  |  | 31 |  |  | 516 |  |  | 397 |  |  | 32 |  |  | 32 |  |  | 460 |
Genvoya |  | 455 |  |  | 56 |  |  | 29 |  |  | 540 |  |  | 482 |  |  | 72 |  |  | 29 |  |  | 582 |
Odefsey |  | 267 |  |  | 74 |  |  | 11 |  |  | 351 |  |  | 255 |  |  | 97 |  |  | 12 |  |  | 364 |
Stribild |  | 19 |  |  | 5 |  |  | 2 |  |  | 26 |  |  | 24 |  |  | 8 |  |  | 2 |  |  | 33 |
Truvada |  | 32 |  |  | 3 |  |  | 7 |  |  | 42 |  |  | 24 |  |  | 5 |  |  | 5 |  |  | 34 |
Revenue share - Symtuza(1) |  | 84 |  |  | 33 |  |  | 3 |  |  | 120 |  |  | 80 |  |  | 42 |  |  | 4 |  |  | 126 |
Other HIV(2) |  | 10 |  |  | 7 |  |  | 3 |  |  | 20 |  |  | 5 |  |  | 9 |  |  | 4 |  |  | 18 |
Total HIV |  | 3,778 |  |  | 521 |  |  | 326 |  |  | 4,626 |  |  | 3,383 |  |  | 562 |  |  | 282 |  |  | 4,228 |
Oncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cell Therapy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tecartus |  | 56 |  |  | 29 |  |  | 4 |  |  | 88 |  |  | 53 |  |  | 20 |  |  | — |  |  | 73 |
Yescarta |  | 217 |  |  | 133 |  |  | 30 |  |  | 380 |  |  | 193 |  |  | 85 |  |  | 17 |  |  | 295 |
Total Cell Therapy |  | 272 |  |  | 162 |  |  | 34 |  |  | 469 |  |  | 246 |  |  | 105 |  |  | 17 |  |  | 368 |
Trodelvy |  | 189 |  |  | 53 |  |  | 17 |  |  | 260 |  |  | 120 |  |  | 35 |  |  | 3 |  |  | 159 |
Total Oncology |  | 462 |  |  | 215 |  |  | 51 |  |  | 728 |  |  | 366 |  |  | 141 |  |  | 21 |  |  | 527 |
Liver Disease |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Chronic hepatitis C virus (“HCV”)
Ledipasvir/Sofosbuvir(3) |  | 8 |  |  | 2 |  |  | 5 |  |  | 15 |  |  | 6 |  |  | 4 |  |  | 13 |  |  | 23 |
Sofosbuvir/Velpatasvir(4) |  | 223 |  |  | 84 |  |  | 90 |  |  | 397 |  |  | 227 |  |  | 75 |  |  | 74 |  |  | 376 |
Other HCV(5) |  | 28 |  |  | 9 |  |  | 3 |  |  | 40 |  |  | 30 |  |  | 16 |  |  | 3 |  |  | 49 |
Total HCV |  | 259 |  |  | 95 |  |  | 98 |  |  | 452 |  |  | 263 |  |  | 94 |  |  | 91 |  |  | 448 |
Chronic hepatitis B virus (“HBV”) / hepatitis delta virus (“HDV”)
Vemlidy |  | 96 |  |  | 10 |  |  | 113 |  |  | 219 |  |  | 97 |  |  | 9 |  |  | 89 |  |  | 195 |
Viread |  | 1 |  |  | 6 |  |  | 14 |  |  | 21 |  |  | 3 |  |  | 6 |  |  | 15 |  |  | 24 |
Other HBV/HDV(6) |  | — |  |  | 20 |  |  | — |  |  | 20 |  |  | — |  |  | 15 |  |  | — |  |  | 16 |
Total HBV/HDV |  | 97 |  |  | 35 |  |  | 127 |  |  | 259 |  |  | 100 |  |  | 30 |  |  | 104 |  |  | 234 |
Total Liver Disease |  | 356 |  |  | 131 |  |  | 225 |  |  | 711 |  |  | 363 |  |  | 124 |  |  | 195 |  |  | 682 |
Veklury |  | 97 |  |  | 52 |  |  | 107 |  |  | 256 |  |  | 41 |  |  | 126 |  |  | 278 |  |  | 445 |
Other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AmBisome |  | 20 |  |  | 69 |  |  | 61 |  |  | 151 |  |  | 15 |  |  | 63 |  |  | 54 |  |  | 132 |
Letairis |  | 39 |  |  | — |  |  | — |  |  | 39 |  |  | 49 |  |  | — |  |  | — |  |  | 49 |
Other(7) |  | 26 |  |  | 10 |  |  | 17 |  |  | 53 |  |  | 37 |  |  | 26 |  |  | 13 |  |  | 76 |
Total Other |  | 85 |  |  | 80 |  |  | 78 |  |  | 243 |  |  | 101 |  |  | 88 |  |  | 67 |  |  | 256 |
Total product sales |  | 4,777 |  |  | 999 |  |  | 788 |  |  | 6,564 |  |  | 4,254 |  |  | 1,042 |  |  | 842 |  |  | 6,138 |
Royalty, contract and other revenues |  | 6 |  |  | 28 |  |  | 1 |  |  | 35 |  |  | 85 |  |  | 34 |  |  | 2 |  |  | 122 |
Total revenues |  | $ | 4,784 |  |  | $ | 1,027 |  |  | $ | 789 |  |  | $ | 6,599 |  |  | $ | 4,339 |  |  | $ | 1,076 |  |  | $ | 844 |  |  | $ | 6,260 |
|  | Six Months Ended June 30, 2023 |  | Six Months Ended June 30, 2022
(in millions) |  | U.S. |  | Europe |  | Other International |  | Total |  | U.S. |  | Europe |  | Other International |  | Total
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HIV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biktarvy |  | $ | 4,600 |  |  | $ | 606 |  |  | $ | 449 |  |  | $ | 5,656 |  |  | $ | 3,801 |  |  | $ | 529 |  |  | $ | 376 |  |  | $ | 4,707 |
Complera/Eviplera |  | 27 |  |  | 37 |  |  | 6 |  |  | 70 |  |  | 37 |  |  | 55 |  |  | 7 |  |  | 99 |
Descovy |  | 855 |  |  | 50 |  |  | 60 |  |  | 965 |  |  | 708 |  |  | 64 |  |  | 63 |  |  | 834 |
Genvoya |  | 872 |  |  | 111 |  |  | 58 |  |  | 1,041 |  |  | 939 |  |  | 149 |  |  | 76 |  |  | 1,164 |
Odefsey |  | 497 |  |  | 149 |  |  | 22 |  |  | 668 |  |  | 487 |  |  | 193 |  |  | 23 |  |  | 703 |
Stribild |  | 39 |  |  | 11 |  |  | 4 |  |  | 55 |  |  | 46 |  |  | 16 |  |  | 5 |  |  | 66 |
Truvada |  | 55 |  |  | 7 |  |  | 12 |  |  | 74 |  |  | 52 |  |  | 9 |  |  | 11 |  |  | 72 |
Revenue share - Symtuza(1) |  | 182 |  |  | 70 |  |  | 7 |  |  | 259 |  |  | 166 |  |  | 86 |  |  | 6 |  |  | 258 |
Other HIV(2) |  | 15 |  |  | 8 |  |  | 6 |  |  | 29 |  |  | 10 |  |  | 13 |  |  | 9 |  |  | 33 |
Total HIV |  | 7,142 |  |  | 1,049 |  |  | 624 |  |  | 8,816 |  |  | 6,245 |  |  | 1,112 |  |  | 577 |  |  | 7,935 |
Oncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cell Therapy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tecartus |  | 114 |  |  | 56 |  |  | 6 |  |  | 177 |  |  | 100 |  |  | 35 |  |  | 1 |  |  | 136 |
Yescarta |  | 427 |  |  | 254 |  |  | 58 |  |  | 739 |  |  | 318 |  |  | 162 |  |  | 26 |  |  | 506 |
Total Cell Therapy |  | 542 |  |  | 310 |  |  | 65 |  |  | 916 |  |  | 418 |  |  | 197 |  |  | 27 |  |  | 642 |
Trodelvy |  | 351 |  |  | 107 |  |  | 23 |  |  | 482 |  |  | 240 |  |  | 61 |  |  | 5 |  |  | 305 |
Total Oncology |  | 893 |  |  | 417 |  |  | 88 |  |  | 1,398 |  |  | 658 |  |  | 258 |  |  | 32 |  |  | 947 |
Liver Disease |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HCV
Ledipasvir/Sofosbuvir(3) |  | 12 |  |  | 9 |  |  | 10 |  |  | 30 |  |  | 19 |  |  | 8 |  |  | 31 |  |  | 58 |
Sofosbuvir/Velpatasvir(4) |  | 427 |  |  | 174 |  |  | 181 |  |  | 782 |  |  | 389 |  |  | 157 |  |  | 159 |  |  | 706 |
Other HCV(5) |  | 51 |  |  | 27 |  |  | 6 |  |  | 85 |  |  | 54 |  |  | 24 |  |  | 5 |  |  | 83 |
Total HCV |  | 491 |  |  | 209 |  |  | 197 |  |  | 897 |  |  | 462 |  |  | 189 |  |  | 196 |  |  | 847 |
HBV/HDV
Vemlidy |  | 183 |  |  | 19 |  |  | 216 |  |  | 418 |  |  | 177 |  |  | 18 |  |  | 199 |  |  | 394 |
Viread |  | 1 |  |  | 12 |  |  | 28 |  |  | 40 |  |  | 3 |  |  | 12 |  |  | 32 |  |  | 47 |
Other HBV/HDV(6) |  | — |  |  | 31 |  |  | — |  |  | 31 |  |  | — |  |  | 28 |  |  | — |  |  | 28 |
Total HBV/HDV |  | 183 |  |  | 62 |  |  | 244 |  |  | 489 |  |  | 180 |  |  | 57 |  |  | 232 |  |  | 470 |
Total Liver Disease |  | 674 |  |  | 271 |  |  | 441 |  |  | 1,386 |  |  | 642 |  |  | 247 |  |  | 427 |  |  | 1,317 |
Veklury |  | 349 |  |  | 163 |  |  | 317 |  |  | 829 |  |  | 843 |  |  | 430 |  |  | 708 |  |  | 1,980 |
Other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AmBisome |  | 27 |  |  | 129 |  |  | 111 |  |  | 267 |  |  | 40 |  |  | 129 |  |  | 107 |  |  | 275 |
Letairis |  | 70 |  |  | — |  |  | — |  |  | 70 |  |  | 92 |  |  | — |  |  | — |  |  | 92 |
Other(7) |  | 56 |  |  | 22 |  |  | 26 |  |  | 105 |  |  | 63 |  |  | 41 |  |  | 22 |  |  | 125 |
Total Other |  | 153 |  |  | 152 |  |  | 137 |  |  | 442 |  |  | 195 |  |  | 169 |  |  | 129 |  |  | 493 |
Total product sales |  | 9,211 |  |  | 2,052 |  |  | 1,607 |  |  | 12,870 |  |  | 8,582 |  |  | 2,216 |  |  | 1,873 |  |  | 12,672 |
Royalty, contract and other revenues |  | 25 |  |  | 54 |  |  | 3 |  |  | 81 |  |  | 112 |  |  | 61 |  |  | 5 |  |  | 178 |
Total revenues |  | $ | 9,236 |  |  | $ | 2,106 |  |  | $ | 1,610 |  |  | $ | 12,951 |  |  | $ | 8,694 |  |  | $ | 2,277 |  |  | $ | 1,878 |  |  | $ | 12,850 |
_______________________________ (1) Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”). (2) Includes Atripla, Emtriva, Sunlenca and Tybost. (3) Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC. (4) Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC. (5) Includes Vosevi and Sovaldi. (6) Includes Hepcludex and Hepsera. (7) Includes Cayston, Jyseleca, Ranexa and Zydelig.
Summary of Revenues from Major Customers | The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:
|  | Three Months Ended |  | Six Months Ended
|  | June 30, |  | June 30,
(as a percentage of total revenues) |  | 2023 |  | 2022 |  | 2023 |  | 2022
AmerisourceBergen Corporation |  | 19 | % |  | 17 | % |  | 18 | % |  | 18 | %
Cardinal Health, Inc. |  | 27 | % |  | 26 | % |  | 27 | % |  | 24 | %
McKesson Corporation |  | 20 | % |  | 20 | % |  | 20 | % |  | 20 | %
Summary of Revenues Recognized from Performance Obligations Satisfied in Prior Periods | The following table summarizes revenues recognized from performance obligations satisfied in prior periods:
|  | Three Months Ended |  | Six Months Ended
|  | June 30, |  | June 30,
(in millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022
Revenue share with Janssen and royalties for licenses of intellectual property |  | $ | 158 |  |  | $ | 197 |  |  | $ | 350 |  |  | $ | 381 |
Changes in estimates |  | $ | 77 |  |  | $ | 16 |  |  | $ | 237 |  |  | $ | 246 |
Summary of Contract Balances | The following table summarizes our contract balances:
(in millions) |  | June 30, 2023 |  | December 31, 2022
Contract assets(1) |  | $ | 130 |  |  | $ | 171 |
Contract liabilities(2) |  | $ | 103 |  |  | $ | 102 |
________________________________ (1) Consists of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation. (2) Generally results from receipt of advance payment before our performance under the contract.

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of expected timing for satisfying remaining performance obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer. + References No definition available. + Details
Name: | us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration